相关实验视频

Updated: Jun 17, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

ZBTB46协调血管新生和免疫力,以控制瘤的结果

Ashraf Ul Kabir¹, Carisa Zeng¹, Madhav Subramanian¹

¹Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Nature immunology

|August 12, 2024

概括

转录因子ZBTB46调节瘤血管生长 (血管生成) 和免疫反应. 降低ZBTB46的调节促进了瘤的生长,而它的恢复则限制了它,提供了治疗潜力.

科学领域:

癌症生物学癌症生物学
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

瘤血管新生和免疫在癌症进展过程中相反相关.
ZBTB46是一种转录因子,也是古典树突细胞 (DC) 的标记物.

研究的目的:

研究ZBTB46在调节瘤血管生成和免疫方面的作用.
探索ZBTB46在癌症治疗中的治疗潜力.

主要方法:

对瘤细胞中ZBTB46表达和人类癌症数据的分析.
研究ZBTB46下调和强制表达对瘤微环境 (TME) 的影响.
对内皮细胞和骨髓祖先的机制研究.

主要成果:

瘤衍生因素降低了DC和内皮细胞中的ZBTB46,促进了带有功能障碍的血管和免疫抑制的前瘤TME.
低ZBTB46表达与人类癌症的预后不佳相关.
强制ZBTB46表达能使瘤血管正常化,并促进免疫刺激性TME.
ZBTB46通过抑制Cebpb.通过抑制Cebpb.调节骨髓系谱倾斜.
在临床前模型中,ZBTB46 mRNA治疗与抗PD1免疫疗法相结合改善了瘤管理.

结论:

在癌症中,ZBTB46是瘤血管生成和骨髓系谱倾斜的关键调节者.
维持ZBTB46表达可以将TME重新编程到抗瘤状态.
ZBTB46代表了增强癌症免疫疗法的潜在治疗标.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...